ResearcherUniversity of MichiganActive in the last 2 years
Nouri Neamati
Matched on ORCID iD 0000-0003-3291-7131; OpenAlex author ID A5023220693; NIH RePORTER profile ID 6663522. Sources: OpenAlex.
Their work
- Papers
- 14 (first author 0, last author 12)
- Trials
- 0
- Grants
- 3
- Labs led
- 2
- Collaborators
- 21
2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 2 papers, 1 grant · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers, 1 grant · 2024: none · 2025: 1 paper · 2026: 1 grant
Papers 14
- Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. Last author DOI 10.1021/acs.jmedchem.4c03159↗
- Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer. Last author DOI 10.1021/acs.jmedchem.2c01769↗
- First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cancer. Last author DOI 10.1021/acsptsci.3c00069↗
- Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. Last author DOI 10.1021/acs.jmedchem.1c01934↗
- Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer. Last author DOI 10.1021/acs.jmedchem.1c02207↗
- The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress-Mediated Apoptosis in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-20-1540↗
- Discovery of Mitochondrial Transcription Inhibitors Active in Pancreatic Cancer Cells. Last author DOI 10.1002/cmdc.202000494↗
- UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2020.100834↗
- Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines. Last author DOI 10.1016/j.ejmech.2018.09.037↗
- Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1021/acs.jmedchem.7b01463↗
- Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells. Co-author DOI 10.1021/acs.jmedchem.5b01571↗
- Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells. Last author DOI 10.1111/bph.12855↗
- Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer. Last author DOI 10.1016/j.bbagen.2013.08.005↗
- Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0054346↗
Grants 3
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mats E. Ljungman · 7 shared papers, 1 shared grant, 2018–2023 · strength 1.51
- Grant Targeting the RNA Exosome for Cancer Therapeutics R01CA213214↗
- Paper First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cance… DOI 10.1021/acsptsci.3c00069↗
- Paper Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreati… DOI 10.1021/acs.jmedchem.1c02207↗
- Yibin Xu · 5 shared papers, 2020–2025 · strength 0.95
- Paper Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. DOI 10.1021/acs.jmedchem.4c03159↗
- Paper First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cance… DOI 10.1021/acsptsci.3c00069↗
- Paper Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreati… DOI 10.1021/acs.jmedchem.2c01769↗
- Joyeeta Roy · 4 shared papers, 2022–2025 · strength 0.84
- Paper Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. DOI 10.1021/acs.jmedchem.4c03159↗
- Paper First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cance… DOI 10.1021/acsptsci.3c00069↗
- Paper Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreati… DOI 10.1021/acs.jmedchem.2c01769↗
- Duxin Sun · 3 shared papers, 2022–2025 · strength 0.64
- Paper Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer. DOI 10.1021/acs.jmedchem.4c03159↗
- Paper Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreati… DOI 10.1021/acs.jmedchem.2c01769↗
- Paper Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01934↗
- Vaibhav Sahai · 1 shared grant, 2023 · strength 0.61
- Ding Xue · 3 shared papers, 2021–2023 · strength 0.51
- Paper First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cance… DOI 10.1021/acsptsci.3c00069↗
- Paper Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01934↗
- Paper The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress-Mediated Apoptosis in Pancreatic Cancer. DOI 10.1158/0008-5472.can-20-1540↗
- Yuting Kuang · 3 shared papers, 2015–2021 · strength 0.31
- Paper The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress-Mediated Apoptosis in Pancreatic Cancer. DOI 10.1158/0008-5472.can-20-1540↗
- Paper Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1021/acs.jmedchem.7b01463↗
- Paper Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer c… DOI 10.1111/bph.12855↗
- Mario Sechi · 4 shared papers, 2014–2018 · strength 0.29
- Paper Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1021/acs.jmedchem.7b01463↗
- Paper Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer c… DOI 10.1111/bph.12855↗
- Paper Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells. DOI 10.1021/acs.jmedchem.5b01571↗
- Divya Pathania · 3 shared papers, 2014–2016 · strength 0.18
- Paper Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer c… DOI 10.1111/bph.12855↗
- Paper Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells. DOI 10.1021/acs.jmedchem.5b01571↗
- Paper Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer. DOI 10.1016/j.bbagen.2013.08.005↗
- Yuting Kuang · 1 shared paper, 2022 · strength 0.15
- Amy Shiu Lee · 1 shared paper, 2021 · strength 0.13
- Soma Samanta · 1 shared paper, 2021 · strength 0.13
- Vanna Sanna · 2 shared papers, 2014–2016 · strength 0.11
- Wen‐Ming Chen · 1 shared paper, 2020 · strength 0.11
- Shuai Hu · 1 shared paper, 2018 · strength 0.11
- Theodore Steven Lawrence · 1 shared paper, 2020 · strength 0.09
- Alnawaz Rehemtulla · 1 shared paper, 2020 · strength 0.09
- Meredith Ann Morgan · 1 shared paper, 2020 · strength 0.09
- Carl G. Engelke · 1 shared paper, 2020 · strength 0.09
- Yajing Liu · 1 shared paper, 2020 · strength 0.09
- Yumna Shabaik · 1 shared paper, 2013 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.